American Society for Gastrointestinal Endoscopy Includes WATS3D in Its New Practice Guideline for the Screening and Surveillance of Barrett’s Esophagus

SUFFERN, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- CDx Diagnostics, developer of the WATS3D diagnostic platform for the screening and surveillance of Barrett’s esophagus (BE), a known precursor to esophageal cancer (EC), today announced that the American Society for Gastrointestinal Endoscopy (ASGE) has included WATS3D in its Standards of Practice Committee’s guideline for the screening and surveillance of BE. A copy of the Standards of Practice Committee’s guideline can be found here.

“It is our hope that broader use of WATS3D can potentially transform EC into a preventable disease. I would like to thank the physicians who have participated in our clinical studies for their guidance and dedication as well as the CDx team led by Dr. Mark Rutenberg for enabling us to reach this pivotal milestone today,” said William Huffnagle, CEO of CDx Diagnostics.

Since esophageal dysplasia is both highly focal and typically invisible, the effectiveness of upper endoscopy is widely recognized to be limited by the high rate of false-negative sampling error associated with standard 4-quadrant random biopsy. WATS3D, or Wide Area Transepithelial Sampling with 3D Tissue Analysis, addresses this limitation by using an abrasive sampling brush to create a wide area tissue sample that unlike standard cytology instruments also captures the full thickness of the epithelium, penetrating into the submucosa. This uniquely comprehensive tissue sample had not been attempted before since it is up to 50X thicker than the depth of field of a standard laboratory microscope. CDx Diagnostics invested over $80M in the development of a three-dimensional computer image analysis system that creates a 3D Micro-Biopsy view of the specimen for review by an artificial intelligence-based neural network system that highlights to any WATS3D certified pathologist potential abnormality found in this complex tissue specimen.

“This important change to the ASGE practice guideline for BE was based on a systematic review of the available literature and reflects consistent findings in multiple studies with prospectively collected data from over 15,000 patients who had WATS3D in addition to forceps biopsies,” said Michael S. Smith, MD, MBA, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai St. Luke's Hospitals, the author of the largest prospective community based study of WATS3D.

“Early detection and treatment of dysplasia has radically reduced deaths from cervical and colon cancers, but has had limited utility in reducing EC deaths partly due to the limitations of screening and surveillance protocols that rely on a tiny forceps biopsy to detect a small area of invisible precancerous change,” said Mark Rutenberg, PhD, MSEE, Founder and Chief Scientific Officer of CDx. “Adjunctive use of WATS3D in more than 250,000 patients, over 10 years, in both academic and community settings, has shown that it effectively addresses this limitation. Moreover, large published prospective trials from real world-community practice settings have demonstrated increased detection of dysplasia and Barrett’s by more than 200% and 100% respectively.”

“The quality of evidence supporting routine adjunctive use of WATS3D is at least as high as that which supports screening and surveillance endoscopy itself,” said Charles J. Lightdale, MD, of the Columbia University Medical Center and one of the authors of a 16 site academic center clinical trial of WATS3D which found that it increased the detection of the smallest, most elusive, and most dangerous form of dysplasia (HGD) by over 400%, even when compared to the meticulous endoscopy and random biopsy performed in specialty BE centers. Dr. Lightdale continued: “This ASGE recommendation recognizes that the incorporation of WATS3D into the routine clinical practice of both community and academic gastroenterology will provide an important benefit to patients by helping to ensure that their chronic heartburn and/or BE will not be allowed to develop into a devastating disease.”

Dr. Michael Smith served as Co-Principal Investigator on the National Clinical Trial and has received compensation as a consultant to CDx Diagnostics.

Dr. Charles Lightdale participated as one of the investigators in a multicenter, academic clinical trial of WATS3D and has received compensation as a consultant to CDx Diagnostics.

About Esophageal Cancer & WATS3D
Esophageal adenocarcinoma (EA) is one of the fastest growing and most fatal cancers in the United States, with an incidence that has quadrupled in men over the past two decades. It is estimated that approximately 17,650 new cases of EA will be diagnosed this year, resulting in approximately 16,080 deaths. EA can be prevented if it is detected and treated while still a harmless precancerous change which is the motivation for the millions of upper endoscopies performed each year on patients which chronic GERD and Barrett’s esophagus. A key factor limiting the effectiveness of this strategy is the fact that esophageal precancer is both highly focal and invisible and that random biopsy sampling tests less than 5% of the known or suspected BE segment. The impact of these limitations is significant, as a previously reported study showed that 25% of cancer patients diagnosed with EC had undergone FB in the previous two years.

In contrast, WATS3D samples a much greater tissue area, enabling detection of dysplastic and abnormal cells that are located between FB samples. The wider sampling area with WATS3D sharply increases the routine detection of BE and ED compared with FB.

Critically, the computer synthesized WATS3D image presents an in vivo, en face view of the gland to the pathologist — allowing for a definitive diagnosis of dysplasia in cases that would otherwise be reported as “indefinite.”

Additionally, the WATS3D computer-assisted technology yields sharply higher inter-observer agreement among pathologists compared with FB. This is because the WATS3D neural network highlights the most suspicious areas on this computer synthesized image areas for consistent pathologist review.

To learn more about WATS3D, and to access our library of photos and videos, visit https://www.cdxdiagnostics.com/media-resources/.

About WATS3D

WATS3D addresses the major inadequacies inherent in current random forceps biopsy testing of the esophagus. In just a few minutes, endoscopists can easily obtain a wide area, full-thickness transepithelial specimen for computer-assisted 3D laboratory analysis prior to diagnosis by any WATS3D certified pathologist. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both Barrett’s esophagus and esophageal dysplasia. The high sensitivity and inter-observer agreement of WATS3D is due to the larger tissue area sampled, and the proprietary 3-Dimensional computer imaging system that is based on an artificial intelligence algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.wats3d.com.

About CDx Diagnostics
CDx Diagnostics’ mission is to provide clinicians with easily implemented, cost effective tools to preempt cancer through enhanced detection of precancerous cellular changes. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Routine clinical use of CDx testing has already detected thousands of dangerous precancerous that would otherwise have been missed in time for effective endoscopic treatment and application of the CDx Diagnostics platform to prevent cancers of the bile duct, stomach, and IBD affected colon is currently in progress. CDx Diagnostics is a Galen Partners portfolio company.

Contact
Chantal Beaudry or John Guerriero for CDx Diagnostics
cbeaudry@lazarpartners.com
jguerriero@lazarpartners.com
212-867-1762 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/33cd146f-9e78-4186-914f-48c6c0e9c68a

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fd18cf92-5143-431f-936e-1d48b6ac89ac

Life Image Announces Launch of Real World Imaging™ (RWI™) to Improve Effectiveness of Real World Evidence Programs for Life Sciences and Artificial Intelligence-Led Innovation

Life Image Represents the Only Company Providing Large, Heterogeneous, De-Identified and Linkable Imaging Data Sets that Integrate to Longitudinal Clinical Outcomes

Newton, Mass. – September 3, 2019 – Life Image, the world’s largest medical evidence network for clinical and imaging data, today announced the launch of its new Real World Imaging (RWI™) offering to respond to researcher needs for maturing insights and accelerating drug development decisions. With its digital platform that is powered by industry-leading interoperability standards, Life Image specializes in ‘living’ or evolving data sets of novel imaging that’s linkable to other clinical information. Life Image’s RWI™ will also be used to train artificial intelligence (AI) models demanding deeper accuracy and sensitivity across diverse data sets.

Life Image’s RWI™ ‘living’ data sets represent hundreds of thousands of patients, tens of millions of images and hundreds of thousands of associated reports and studies categorized by more than 25 anatomical parts including head, lung, breast, chest and more. This heterogeneous and continuously growing data represents an expanding variety of demographics, temporal data, linked longitudinal records and virtually every global manufacturer across all modalities.

Imaging data, especially for Real World Evidence (RWE), has historically been difficult, if not impossible, to access, retrieve, view, de-identify and normalize at-scale, even though it provides clinically material insights for a growing number of therapies. Since 2008, Life Image has been the market leader using common interoperability standards to solve the many technical, procedural and structural barriers that have effectively segregated imaging data into unconnected data silos.

“The time has finally arrived that imaging can be utilized as an effective part of the RWE process by eliminating manual processing and compliance errors, providing access to large heterogeneous data sets, and doing so at the speed of the internet,” said Matthew A. Michela, CEO and President, Life Image. “With RWI™, Life Image is expanding its focus on helping researchers and innovators capture the full potential of RWE by providing ‘living’ data sets that grow and become even more meaningful over time. This makes it possible to answer questions as they arise as opposed to answering one question in a limited manner retrospectively, such as carefully controlled clinical trials. The potential benefits are innumerable for patients, payers, population health initiatives, artificial intelligence, and drug and device development.”

RWE is now a global mandate for drug development and pharmacovigilance from the Food and Drug Administration (FDA) in the U.S. as well as regulatory agencies in Europe. RWE supports the process of establishing better arguments across the drug development lifecycle by using clinical, operational, administrative, social and patient-reported outcome information gathered from sources that capture this data at the time of the patient care transaction, as opposed to historical methods of data collection from a controlled clinical trial setting.

Common sources of Real World Data (RWD) such as labs, pharmacy, EHR and medical claims data unfortunately have limited ability to meaningfully capture a patient’s clinical circumstances. Biases exist in these sources of data, especially in oncology and cardiology, due to the type of data being collected (e.g. claims or billing codes) or due to limited access to sources of this data (reinforcing homogeneity). These challenges often result in inaccurate representations of the patient’s or population’s actual condition or the impact of a treatment. Enhancing this type of data with imaging and unstructured data sets elevates the ability to validate the effectiveness of research and statistical models, accelerating the ability to improve protocols and patient outcomes.

In addition to RWI™ data, Life Image also provides value-added services to researchers and innovators including end-to-end management for de-identification, data curation and linking across medical claims, EHR, genetics and other phenotypical commercial and public data assets.

About Life Image
Life Image is the world’s largest medical evidence network providing access to points of care and curated clinical and imaging data. It is the only company in the market today with Real World Imaging™ that provides large-scale, heterogeneous, de-identified imaging sets that are linkable to other longitudinal data. Founded in 2008, Life Image has created a digital platform using industry-leading interoperability standards to connect 10,000 facilities with more than 150,000 U.S. providers and 58,000 global clinics. Its network of hospitals, physicians, patients, life sciences, medical devices and telehealth is interconnected with a technical ecosystem of EHRs, PACS, AI solutions, cloud environments and analytics platforms.

For more information about Life Image, please visit www.lifeimage.com, visit its blog and follow the company on TwitterFacebook, and LinkedIn.

###

Media Contact
Ashley Owen
Aria Marketing for Life Image
(617) 332-9999 x216
aowen@ariamarketing.com

NextGate and Life Image Partner to Deliver Trusted Ecosystem of Clinical and Imaging Data

Partnership will enable a single, comprehensive view of patient information across a global-sharing network of clinical, imaging, medical device and pharmaceutical data.

 

PASADENA, Calif. and NEWTON, Mass., June 25, 2019 – NextGate, the global leader in healthcare enterprise identification, and Life Image, the world’s largest global network for sharing clinical and imaging data that is powered by industry leading interoperability standards, today announced a strategic partnership to meet increasing demand for reliable imaging workflow integration.

Eliminating silos and ensuring that each patient has one and only one record, NextGate and Life Image will help caregivers and researchers optimize care delivery thru their EHR, imaging and other health information systems, forming a solid foundation for data exchange and coordination of care.

Seamless integration of NextGate’s market-leading Enterprise Master Patient Index (EMPI) within the Life Image Interoperability Suite will help to orchestrate accurate, comprehensive patient demographic information across an extensive network of 1,500 U.S. hospitals, 8,000 affiliated sites, 150,000 providers and 58,000 global clinics. The Life Image network— a global ecosystem of clinical, imaging, medical device and pharmaceutical data now integrated into the workflows of 80 percent of all large health systems and academic medical centers in the U.S.—exchanges seven billion imaging files and manages more than 10 million clinical encounters per month.

The partnership furthers NextGate’s position in the global healthcare market as the leader in positive patient identification and solidifies its commitment to helping hospitals overcome the clinical and financial inefficiencies that result from duplicate medical records and data silos.

“Busy clinicians and care managers need high-quality data, tied to the correct patient, in order to make informed, life-saving decisions,” said Life Image President and CEO Matthew A. Michela. “We are delighted to align with NextGate to support all healthcare constituents with a unified health record to deliver the high-quality level of care every patient deserves.”

As organizations transition to value-based care delivery models, the need for a complete and accurate view of patient data across the continuum becomes increasingly critical for greater clinical, operational and financial performance. Inaccurate patient identification costs the U.S. healthcare system $6 billion annually and results in medical errors, data quality issues, administrative waste, and poor patient and provider satisfaction.

“The issue of poor patient identification and duplicate records has grown increasingly complex as more data is generated and more applications are introduced into the healthcare environment,” said NextGate CEO Andy Aroditis. “In the face of accountable, data-driven care, organizations now find themselves under increased pressure to effectively identify, track and manage individuals across care settings. We are delighted to align with Life Image to deliver unprecedented clarity and reliability into one’s medical record for informed clinical-decision making, effective care management, and a seamless patient-provider experience during every encounter.”

 

 

About NextGate
With over 200 customers in four countries, NextGate is the global leader in healthcare enterprise identification. Committed to helping organizations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data, our full suite of identity matching solutions connects the entire healthcare ecosystem to drive critical improvements in quality, efficiency and safety. NextGate’s market-leading EMPI currently manages 300 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges. For more information, visit NextGate.com.

 

About Life Image
With its beginnings in medical image exchange, Life Image now orchestrates the flow of any and all clinical information across the patient’s journey, in real time, to help care teams and researchers make informed decisions. Founded in 2008, Life Image has spent the past decade innovating and building an interoperable network ecosystem connecting hospitals, physicians, patients, pharmaceuticals, medical device, telehealth and EHRs. Today, the Life Image network connects over 1,500 facilities in the United States and 8,000 affiliated sites, including 8 of the top 10 U.S. hospitals, with 150,000 U.S. providers and 58,000 clinics globally. For more information about Life Image, visit: www.lifeimage.com.

 

# # #

 

Media Contacts:
Stephanie Fraser
Director of Communications and Media Relations, NextGate
c: 734-233-1483 | o: 734-399-9336
stephanie.fraser@nextgate.com

 

Ashley Owen
Aria Marketing for Life Image
617-332-9999, x 216
aowen@ariamarketing.com

swyMed Partners with Life Image to Expand Access to Integrated Telestroke Solution to Help Patients at Rural and Community Hospitals Gain Access to Stroke Specialists

Leading Mobile Telemedicine Company Joins Life Image Network to Enhance Telestroke Offering with Robust Imaging and Clinical Data Integration

Newton, Mass. – March 28, 2018 – Life Image, the world’s largest global network for sharing clinical and imaging data that is powered by industry leading interoperability standards, and swyMed, a leading provider of mobile telemedicine solutions, today announced a new strategic partnership to enhance telestroke capabilities. This engagement will improve the ability for physicians to collaborate and coordinate care while using swyMed’s offering by seamlessly integrating relevant clinical and imaging data into the telemedicine encounter. The agreement also deepens swyMed’s ability to connect to neurologists and primary stroke centers, which are already part of the Life Image network. Life Image is currently supporting more than 140 stroke centers within its U.S. network.

This new partnership will advance swyMed’s telestroke solution by combining the exceptional bandwidth management capabilities in its videoconferencing platforms, which are highly beneficial for rural area hospitals, with access to all relevant medical records, diagnostic imaging, and other critical clinical data. This data is made available through the Life Image clinical image exchange, which is integrated into the workflows of 80 percent of all large health systems and academic medical centers in the U.S. The engagement will also provide Life Image hospital customers with a value-added telestroke solution as part of the Life Image Interoperability Suite, to extend neurology departments’ reach beyond the walls of the organization and deliver timely, high-quality care for patients affected by stroke.

“Despite widespread knowledge that every moment counts when it comes to treating acute ischemic stroke, a majority of stroke patients do not receive adequate treatment in time due to lack of access to primary stroke centers and appropriate specialists,” said Evie Jennes, CCO, swyMed. “We have dedicated extensive efforts to innovating solutions to overcome these challenges and optimize outcomes among stoke patients. By engaging with Life Image, we can now provide immediate access to imaging and clinical data to speed up diagnosis and treatment, as well as connect swyMed users to premier neurology centers and leading research facilities through Life Image’s extensive provider network.”

There are several access-related challenges associated with acute stroke treatment, which are further compounded by the fact that diagnosis and treatment are incredibly time-sensitive and require a specialist. Unfortunatelyresearch shows a severe lack of stroke specialists in the U.S.: only 55 percent of Americans reside within 60 miles of a primary stroke center, and there are only an estimated 1,100 neurologists specializing in stroke nationwide. This new strategic partnership between swyMed and Life Image will address these data access and specialist shortage issues by offering immediate connectivity, even in the most bandwidth-challenged areas, to stroke specialists across the U.S., and integrating all relevant medical data into the telemedicine encounter to allow diagnosis and treatment to begin before the patient arrives at the hospital.

“Providers have long struggled with interoperability and data-integration issues across systems and locations, and these issues come to a head when caring for a stroke patient. Paramedics and emergency room doctors especially need to immediately reach stroke specialists and provide them with the patient’s neurological exam and other imaging and clinical data in order to achieve the best-possible outcome for the patient,” said Matthew A. Michela, President and CEO, Life Image. “We see this partnership with swyMed as an important opportunity to advance the clinical practice of telestroke. Whether it’s a rural hospital with poor bandwidth or a hospital without stroke specialists, this new engagement will benefit all providers dealing with stroke management by uniting swyMed’s cutting-edge telemedicine platform with our powerful global network of data and integration into thousands of provider workflows nationwide.”

Life Image’s interoperable solution, which integrates into existing workflows, orchestrates the flow of more than 10 million clinical encounters per month. The network connects 1,500 U.S. facilities, 8,000 affiliated sites, 150,000 U.S. providers, and 58,000 global clinics with a broader ecosystem of patients, life sciences, medical device companies, and telemedicine companies.

 

About Life Image

With its beginnings in medical image exchange, Life Image now orchestrates the flow of any and all clinical information across the patient’s journey, in real time, to help care teams and researchers make informed decisions. Founded in 2008, Life Image has spent the past decade innovating and building an interoperable network ecosystem connecting hospitals, physicians, patients, pharmaceuticals, medical device, telehealth and EHRs. Today, the Life Image network connects over 1,500 facilities in the United States and 8,000 affiliated sites, including 8 of the top 10 U.S. hospitals, with 150,000 U.S. providers and 58,000 clinics globally.

For more information about Life Image, please visit: www.lifeimage.com, and check out our blog and follow us on Twitter, Facebook, and LinkedIn.

 

About swyMed

Time-critical mobile telemedicine consults require simple, fast and highly reliable connections. While many solutions fail beyond the hard-wired four walls of a hospital, swyMed’s patented technology expands telemedicine care to places where it was previously unavailable, powering truly mobile exceptional-quality live video encounters, even at the lowest bandwidths. swyMed’s proven, reliable, easy-to-use solutions, including the DOT Telemedicine Backpack and the DOT Mini, give care providers the ability to connect to doctors for real-time video telemedicine — anytime, anywhere. swyMed’s innovative technology is used by providers in rural hospitals to connect to specialists, for Remote Patient Evaluation (RPE), home health, EMS/critical transport, tele-stroke, mobile telestroke and Mobile Integrated Healthcare (MIH) programs in thousands of encounters throughout the United States, Europe, the Middle East and India.

 

Media Contacts

Ashley Owen
Aria Marketing for Life Image
aowen@ariamarketing.com

617-332-9999, x 216

Accessing and incorporating medical imaging data assets to accelerate drug development

By: Matthew Michela 

Real-world evidence (RWE), based on data derived from a wide range of sources outside of a controlled clinical research setting, is increasingly important in improving patient outcomes and value across the healthcare system.

Diagnostic imaging is among the most important data source that has not yet been effectively integrated into RWE. Technical and administrative problems have held it back, but the time has finally come when imaging can become a fundamental part of RWE.

RWE as a mandate: From optional to integral

Looking ahead in drug development, generating reproducible evidence from multiple data assets is one of the key metrics for success at an inflection point. With the rapid pace to acquire and govern data assets, improving sensitivity behind hypothesis generation and early discovery, the biggest need for imaging and pathology data sits inside oncology and neurology pipelines.

Regulatory agencies are increasingly mandating RWE’s use in a wide variety of contexts. The FDA recently issued a guidance on the use of RWE, and the European Medicines Agency uses RWE for certain types of approval. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is using RWE for some types of drug efficacy demonstration.

As a result, RWE is being included earlier in the evidence management life cycle to influence better trial design and feasibility, better trial execution (cohort identification, recruitment, adherence, and clinical end-point access), and better insights into post-market access.

Thus, the mounting pressure to partner with provider networks with the right data access strategy to improve identification of novel safety signals on drugs, devices, and other therapeutic interventions comes directly from regulators, public and private payers, and prescribers. While randomized clinical trials (RCT) provide the necessary measure of effectiveness under ideal conditions, RWE provides the context on how the intervention works in the real world for patient populations in their everyday environments. And it does so both rapidly and over time, enabling continuous feedback.

The real power behind moving RWE earlier in the lifecycle is that it is an experience-based living data set that constantly updates, allowing for questions to be answered and refined as the basis for new insights instead of waiting until Phase III or later.

Solving the accessibility challenge in imaging

In the modern era, there is virtually no impactful medical procedure or therapy that does not have diagnostic imaging associated with it. Yet, while the healthcare industry has spent decades standardizing claims, pharmacy, lab, and electronic health records (EHRs), it has thus far failed to effectively standardize and incorporate imaging at scale.

There is a high degree of non-interoperability in clinical imaging. One contributing factor is that the science of imaging is changing rapidly, with new generations of devices appearing annually. These are important developments influencing the quality of care, but rapid change makes it difficult to maintain standardization essential for interoperable image management.

Additionally, medical images have dramatically increased in file size. An MRI might be a moving digital file composed of thousands of separate images, requiring 500 gigabytes to be transferred and stored. This is a far cry from managing a five-digit current procedure terminology (CPT) code.

Lastly, the lack of common standards made it extraordinarily difficult to access data sets of imaging biomarkers across clinical workflows and across large trial networks globally.

So, despite the recognized need, an entire industry of clinical researchers and data scientists has been built essentially without image data. Up to now, the barriers have been too difficult to surmount.

However, we have reached a point of technological maturity where it is finally possible to acquire large amounts of image data, normalize it, transmit it, store it, and analyze it. This is a definite turning point in the industry. Images can now be aggregated with all of the other data streams that go into RWE.

As of yet, the awareness of this availability of clinical imaging has not fully penetrated the community of those who manage the evidence life cycle, but it’s coming.

One reason, of course, is that the imaging must be processed, integrated, and managed in a specific way in order to be truly useful. And that requires certain hard-earned capabilities.

What is required for clinical image data to be useful for RWE?

While the medical community acknowledges that medical imaging provides high-quality data with material clinical utility, in order to be truly useful for RWE on a broad scale, imaging data must meet five requirements.

  1. Come from a wide range of varied locations
    Data from one hospital network or even group of imaging centers will only provide data on a restricted patient profile with likely inherent bias. The information will inevitably be limited by population, geography, type of care, and physician expertise. Data must be available from a wide range of research and non-research sites.

  2. Represent a large volume from each of those locations
    In addition to the breadth of data from various locations, there must be a large volume of imagery from each location. This is clearly a place where big data is essential. Effective algorithms, driven by deep or machine learning models, can only be developed when they have a vast number of examples to work on, and the lack of context-sensitive imaging data from a large cohort of a heterogenous population has slowed the development and training of useful models.

  3. Be tied closely to the context of clinical decision making
    But in addition to the breadth and depth of data, RWE must also come in the context of clinical decisions, whether diagnosis, treatment, or follow-up—all connected intimately with all of the options, confirmations, and corrections that comprise clinical workflow. RWE’s real strength comes from how it’s generated from practical workflows, how patients adhere to therapy, and how reimbursement affects treatment.

  4. Be device agnostic and fully interoperable
    Imaging has to be easily available from any capture device and in standard formats. Even when images ostensibly come in the same format, images from devices from one manufacturer can differ significantly from those from another and must be normalized to be useful. A high degree of technical interoperability, with the ability to pull data from disparate picture archiving and communications systems (PACS), dermatology cameras, PET scans, or elastography indifferently, is essential.

  5. Be unambiguously indexed to a specific patient
    EHRs have a singular identification of each patient so that each piece of data and each encounter can be mapped to a specific individual. In medical imaging, each device type, storage system, and provider workflow uses different information to reconcile patients. The creation of a master patient index enabling reconciliation of patients with a high degree of confidence is essential for making imaging data available at scale.

Satisfying all five requirements enables a wide range of federated longitudinal queries on integrated, normalized, wide, and deep databases of images.

How to effectively incorporate image data into the entire evidence cycle

We are currently seeing a major consolidation of commercial health information exchange (HIE) networks, as various competitors seek to gain market dominance by becoming aggregators of healthcare data; and the drive for unique and informative data types is escalating.

But there is still no commercial source of real-world data (RWD) that fulfills all the requirements for useful medical image data and integrates into their full RWE offering. Networks that include a market-leading expert in handling large amounts of medical image data will be able to bring badly needed efficiencies to RWE. These new consortia will be able to finally provide the long-desired integration of clinical imaging into RWE.

Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's esophagus:

Analysis from a prospective multicenter community-based study

M S Smith E Ikonomi R Bhuta N Iorio R D Kataria V Kaul S A GrossUS Collaborative WATS Study Group, Diseases of the Esophagus, doy099

Summary

The 4-quadrant forceps biopsy (FB) protocol for identifying Barrett's esophagus (BE) and esophageal dysplasia (ED) suffers from poor sensitivity due to significant sampling error. We investigated the benefit of wide-area transepithelial sampling with 3-dimensional computer-assisted analysis (WATS) used adjunctively to the combination of random and targeted FB in the detection of ED, and as a secondary outcome, BE. In this multicenter prospective trial, community endoscopists at 21 sites utilized WATS as an adjunct to both targeted and random FB in patients undergoing BE screening and surveillance. Investigators alternated taking FB and WATS samples first. WATS specimens were analyzed at CDx Diagnostics (Suffern, NY) while FB samples were analyzed by each site's regular pathologists. Data were de-identified and then aggregated for analysis. Of 12,899 patients enrolled, FB identified 88 cases of ED, and WATS detected an additional 213 cases missed by FB. These 213 cases represented an absolute increase of 1.65%, raising the yield from 0.68% to 2.33%. Adding WATS to FB increased the overall detection of ED by 242% (95% CI: 191%–315%). Fewer than 61 patients needed to be tested with WATS to identify an additional case of ED. The combination of random and targeted FB identified 1,684 cases of BE, and WATS detected an additional 2,570 BE cases. The absolute incremental yield of adding WATS to FB is 19.9%, increasing the rate of detection from 13.1% to 33%. Adding WATS to FB increased the overall detection of BE by 153% (95% CI: 144–162%). The number needed to test with WATS in order to detect an additional case of BE was 5. Whether FB or WATS was done first did not impact the results. In this study, comprised of the largest series of patients evaluated with WATS, adjunctive use of the technique with targeted and random FB markedly improved the detection of both ED and BE. These results underscore the shortcomings of FB in detecting BE-associated neoplasia, which can potentially impact the management and clinical outcomes of these patients.

Read full article with images, tables and references

CVS Health, Sharecare Launch Digital Drug Discount Card

Forbes, Bruce Japsen, Senior Contributor

Digital health company Sharecare has launched a “digital pharmacy savings card” to help the uninsured and those with high deductibles get access to discounts on prescription medicines from CVS Health’s vast pharmacy network.

Known as Sharecare Rx, the discount is different than traditional drug discount cards in that consumers download Sharecare's app and can immediately search for specific medications, prices and pharmacy locations . Financial terms of the Sharecare partnership with CVS weren’t disclosed.

Though Sharecare Rx is initially being touted as for the uninsured or those who lack sufficient drug coverage, executives say it can also serve as a “second opinion” for consumers in any drug plan to compare prices and access to prescription medicines. Sharecare Rx is a new part of Atlanta-based Sharecare’s digital health platform.

“By partnering with CVS Caremark to build Sharecare Rx into our platform, we are removing barriers to empower consumers to truly manage all their health in one place,” Sharecare co-founder and CEO Jeff Arnold, who also founded WebMd, said in a statement accompanying the announcement. “We are also actively working with our health plan and employer partners to integrate their formulary coverage and pricing into Sharecare so their members can seamlessly access their prescription benefits, as well as information and tools to help them adhere to a healthier regimen.”

It’s the latest effort by startups and other new entrepreneurial entrants in the prescription business to help consumers gain better information about the costs and quality of their medicines.


ProMedica Health System to Deploy PeriGen Artificial Intelligence Solution Focused on Improving Outcomes in Childbirth

System Targets Preventable Morbidity and Mortality in Childbirth


CARY, N.C. and TOLEDO, Ohio, Oct. 2, 2018 /PRNewswire/ -- PeriGen, an innovator of perinatal early warning systems, today announced that ProMedica, a not-for-profit integrated health care organization serving 30 states, plans to deploy the company's PeriWatch™ Vigilance™, an artificial intelligence-based maternal-fetal early warning system (EWS), in all of its labor and delivery hospitals. Vigilance is designed to help clinicians identify troubling trends earlier and more consistently than manual assessments and creates a common language for nurses and physicians to assess cases. 

The artificial intelligence-driven technology, developed by PeriGen, is the latest chapter in ProMedica's commitment to lead improvement in Ohio and Michigan's infant and maternal mortality and morbidity rates, which currently rank near the bottom of the nation. The software is designed to be implemented in a matter of weeks and brings an unprecedented level of monitoring to the labor and delivery floor. It does not require replacing any current systems already in place.

"While we invest significantly in training our nurses, we feel this technology will enhance our ability to provide the safest care possible," said Kent Bishop, MD, Chief Medical Officer for ProMedica Physicians and Acute Care. "Using AI to help our nurses assess and consistently identify irregularities is so logical, we considered trying to build our own solution; during our research we found a proven system that we can partner with."

Matthew Sappern, CEO of PeriGen, said that ProMedica's commitment to patient safety is profound: "ProMedica has taken a very visible leadership role in combatting infant and maternal morbidity and mortality and aspires to continuous improvement in this service line."

ABOUT PROMEDICA
ProMedica is a mission-based, not-for-profit integrated healthcare organization headquartered in Toledo, Ohio. It serves communities in 30 states. The organization offers acute and ambulatory care, an insurance company with a dental plan, and post-acute and academic business lines. The organization has more than 70,000 employees, 13 hospitals, 2,700 physicians and advanced practice providers with privileges, 900+ healthcare providers employed by ProMedica Physicians, a health plan, and 450 assisted living facilities, skilled nursing and rehabilitation centers, memory care communities, outpatient rehabilitation clinics, and hospice and home health care agencies. Driven by its Mission to improve your health and well-being, ProMedica has been nationally recognized for its advocacy programs and efforts to address social determinants of health. For more information about ProMedica, please visit www.promedica.org/aboutus.

ABOUT PERIGEN
PeriGen offers innovative perinatal software solutions that incorporate artificial intelligence (AI) to enhance clinical efficiency and standardization of care during childbirth. Led by skilled OB practitioners and IT visionaries, PeriGen has created the PeriWatch platform to provide consistent analysis and efficient display of complex data in real-time to promote better human recognition and communication about impending problems during labor. With PeriWatch, clinicians can spend more time on direct patient care and less time on manual calculations and data manipulation. To learn how to VigilanceTM can improve situational awareness and help manage risk, visit www.perigen.com; follow us on TwitterLinkedInYouTube, and Facebook; or call 984.208.4250 or email.

Media Contact for PeriGen:                                                                                       
Heather Caouette
Amendola Communications
508.579.3894
hcaouette@acmarketingpr.com

SOURCE PeriGen

Related Links

http://perigen.com

Galen Partners completes investment in SMP Pharmacy Solutions, a niche-focused, high-touch specialty pharmacy

Galen teams with SMP’s Founder / CEO and existing management to recapitalize the company

Stamford, CT (July 19, 2018) – Galen Partners, a healthcare-focused growth equity investment firm, announced today that it has completed a majority recapitalization of SMP Pharmacy Solutions. Headquartered in Miami, FL, SMP is a high-touch, service-oriented specialty pharmacy that focuses on niche and complex therapeutic areas such as fertility.  SMP differentiates itself from other specialty pharmacies through its personalized service and its ability to maintain high medication adherence amongst its patients. The financial terms of the transaction have not been disclosed.

“We are excited about the prospect of building upon SMP’s high-touch pharmacy platform,” said Philip Borden, Managing Director at Galen Partners. “Founder & CEO Armando Bardisa and the rest of the SMP team have done a fantastic job of positioning SMP for future growth within fertility and other complex therapeutic areas such as inflammatory diseases, gastroenterology, oncology, and infectious diseases like HIV.” SMP benefits from the significant expansion of specialty drugs, which has been the single biggest driver of the pharmaceutical industry’s growth.

Armando Bardisa, SMP’s Founder and CEO, stated, “We are proud of SMP’s history of delivering quality patient care through personalized service, highly trained and knowledgeable staff, advanced data and analytics, and a company culture centered on teamwork and integrity. On behalf of the entire SMP team, we are excited about our partnership with Galen, and we know SMP will accomplish even greater things with the backing and support of our new partner.”

SMP’s COO Brian Brito added, “From our first meeting with the Galen team, we knew we had met a group of individuals who had an appreciation for what we were all about. Galen Partners brought something far more important than investment capital to the table:  They brought an industry-savvy network of advisors, including Galen Special Investment Partner Michelle Hasson, as well as, a strategic framework for how we might approach building a valuable enterprise.”  Mr. Bardisa and Mr. Brito will continue to lead the SMP team.

About Galen Partners
Founded in 1990, Galen Partners is a leading healthcare-focused growth equity investment firm. With nearly $1 billion invested over six funds, Galen has invested in and helped to build more than 70 companies since the firm’s inception.  Galen continues a tradition of strategic collaboration and partnership with founders and management teams to build healthcare market leaders. Under the direction of the Managing Directors Philip Borden, David Jahns and Zubeen Shroff, Galen seeks to make investments in high-growth healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million.  SMP represents the second investment out of Galen Fund VI.

For more information, please visit www.galen.com.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as legal advisors to Galen. FTI Consulting served as financial advisors to Galen. Monroe Capital provided debt financing for the transaction.

About SMP Pharmacy Solutions
SMP Pharmacy Solutions is a leading high growth specialty pharmacy that provides treatments for a variety of complex disease states. Since 2003, management has grown SMP from a local retail pharmacy to a nationwide specialty pharmacy with licenses in 45 states and strategic partnerships with leading manufacturers and MSOs. SMP differentiates itself from other specialty pharmacies by its industry-leading service, combining customizable patient management and pharmacy programs with access to in-demand therapeutics. SMP has established a nationwide reputation with patients, payors, providers, and manufacturers for delivering true healthcare value to all constituents. SMP has developed specific therapeutic expertise in fertility and rheumatoid arthritis, and has strong experience in dermatology, infectious disease, gastroenterology, osteoporosis, and oncology.

Berger Singerman, LLP served as legal advisors to SMP.  FocalPoint Partners served as investment banking advisor to SMP.

For more information, please visit www.smppharmacy.com

Stacey Bauer
Office: (203) 653-6473
sbauer@galen.com

ASGE Launches Public Service Awareness Campaign to Preempt Esophageal Cancer

NEWS PROVIDED BY
American Society for Gastrointestinal Endoscopy

"We hope that our PSA campaign will encourage more Americans with chronic heartburn to see a gastroenterologist and take advantage of our recently enhanced ability to prevent one of the most rapidly growing cancers in the US," said ASGE President Karen L. Woods, MD, FASGE.

Interested DDW attendees can obtain materials at the ASGE booth (#1733) during DDW June 2-5, 2018 at the Walter E. Washington Convention Center, Washington, DC. The PSA campaign is funded through a partnership with CDx Diagnostics, the provider of WATS3D testing for precancerous cells.

For more information visit www.asge.org/heartburn.

About Gastrointestinal Endoscopy
Gastrointestinal endoscopic procedures allow the gastroenterologist to visually inspect the upper gastrointestinal tract (esophagus, stomach and duodenum) and the lower bowel (colon and rectum) through an endoscope, a thin, flexible device with a lighted end and a powerful lens system. Endoscopy has been a major advance in the treatment of gastrointestinal diseases. For example, the use of endoscopes allows the detection of ulcers, cancers, polyps and sites of internal bleeding. Through endoscopy, tissue samples (biopsies) may be obtained, areas of blockage can be opened and active bleeding can be stopped. Polyps in the colon can be removed, which has been shown to prevent colon cancer.

About the American Society for Gastrointestinal Endoscopy
Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with more than 15,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area.

Contact:
Erich Sandoval
Lazar Partners Ltd. 
Tel: +1 917-497-2867
Email: esandoval@lazarpartners.com

SOURCE American Society for Gastrointestinal Endoscopy

Related Links

http://www.asge.org

Blue Cross and Blue Shield of Minnesota Partners with Sharecare to Provide Health and Wellbeing Solutions

Digital Platform Sets a New Standard for Optimizing Health Through Personalization

EAGAN, Minnesota (May 14, 2018) — Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced that it is partnering with Sharecare, the digital health company that helps people manage all their health in one place, to offer its popular and groundbreaking personalized health platform to Blue Cross commercial customer groups and members starting in 2019. This agreement will provide exclusivity to Blue Cross as the only Minnesota-based plan to offer the Sharecare platform.

In this agreement, Sharecare will serve as the foundation for Blue Cross’ digital health management offerings that are part of the health insurer’s do.® health and wellbeing platform. The do. approach, which can be customized to the unique needs of a specific business and its workforce, is centered around a “small steps” concept that empowers people to take an active role in gradually and consistently improving their own health.

Sharecare provides people with a comprehensive and ultra-personalized health profile that drives personal engagement and connections to relevant information and evidence-based programs. The Sharecare engagement platform includes the following features:

  • RealAge®, Sharecare’s proprietary and scientifically validated health risk assessment, which provides people with an accurate measure of the actual age of their body, versus their calendar age. After completing the assessment, Sharecare members receive personalized content and recommendations aimed at lowering their RealAge. To date, more than 45 million people have taken the RealAge test.
  • AskMD®, Sharecare’s award-winning symptom checker, which can get someone from finding out “what’s wrong” to understanding what they can do about it.
  • Daily tracking and motivation via targeted messaging that can drive long-term health habits.

Additionally, numerous configurable health management options for employers through Blue Cross will be available on the Sharecare platform starting in 2019. Examples include:

  • Customized reward programs to incentivize employees in taking those next steps to improve their health;
  • Wellness challenges to create fun and healthy competition to increase engagement;
  • Health screening options through BioIQ®, which provides employers and their employees an easy-to-use screening platform to help members stay informed and identify opportunities for health improvement; and
  • Powerful analysis and deep insights on the overall health of an employee population, with recommendations on how to address the behaviors and factors that are driving results.

“Sharecare is a great match with the health and wellbeing programs we offer at Blue Cross,” said Cain A. Hayes, president and chief operating officer of the Health Business for Blue Cross and Blue Shield of Minnesota. “Both of our organizations are focused on bringing about real change in people’s health through meaningful experiences and information that inspire action and reward progress. Empowering and encouraging people on their health journeys is at the heart of what we do and is central to our mission of making a healthy difference in people’s lives.”

According to the 2017 state rankings from the Gallup-Sharecare Well-Being Index, Minnesota ranked fourth for overall well-being in the United States. While the state displayed very strong positions in financial, community and physical well-being, it has opportunities to improve in the areas of social and purpose well-being, as well as specific markers including the number of Minnesotans who are overweight (37.8%) or obese (23.9%), and have had high blood pressure (25.2%), high cholesterol (21.2%) or been diagnosed with depression (21.2%) within their lifetime.

“In addition to its leading position in the Gallup-Sharecare Well-Being Index state rankings, Minnesota is widely recognized as one of the most innovative states in the country, and their first-mover status in healthcare is a significant contributor to their reputation in that regard,” said Jeff Arnold, co-founder, chairman and CEO of Sharecare. “We are proud to join forces with Blue Cross not only to push the healthcare innovation envelope further but also inspire and empower the people of Minnesota to live their healthiest, happiest, most productive lives so they, too, can continue to positively impact their communities and our world.”

About Blue Cross and Blue Shield of Minnesota
Blue Cross and Blue Shield of Minnesota, with headquarters in the St. Paul suburb of Eagan, was chartered in 1933 as Minnesota’s first health plan and continues to carry out its charter mission today: to promote a wider, more economical and timely availability of health services for the people of Minnesota. A nonprofit, taxable organization, Blue Cross is the largest health plan based in Minnesota, covering 2.9 million members in Minnesota and nationally through its health plans or plans administered by its affiliated companies. Blue Cross and Blue Shield of Minnesota is an independent licensee of the Blue Cross and Blue Shield Association, headquartered in Chicago. Go to bluecrossmn.com to learn more.

About Sharecare
Sharecare is an independent company providing digital health services to help people manage all their health in one place. The Sharecare platform provides each person – no matter where they are in their health journey – with a comprehensive and personalized health profile, where they can dynamically and easily connect to the information, evidence-based programs and health professionals they need to live their healthiest, happiest and most productive life. In addition to providing individual consumers with direct access to award-winning and innovative frictionless technologies, scientifically validated clinical protocols and best-in-class coaching tools, Sharecare also helps providers, employers and health plans effectively scale outcomes-based health and wellness solutions across their entire populations. To learn more, visit sharecare.com.

Walmart partners with Sharecare to transform the health and wellbeing of their associates and communities

ATLANTA and BENTONVILLE, Ark. (May 8, 2018) – Sharecare, the digital health company helping people manage all their health in one place, and Walmart Inc. (NYSE: WMT) today announced a strategic partnership aimed at improving the health and wellbeing of the retail giant’s associates and their families and friends, as well as the people living in the communities in which their stores operate. This unique collaboration builds on Walmart’s associate wellness strategies and delivers on its commitment to improve the health of its communities.

“Walmart is committed to helping our associates, their families, and communities to improve their overall wellbeing through wellness programs,” said Jacqui Canney, executive vice president, global people, Walmart Inc. “Partnering with Sharecare will provide our associates additional tools to inspire them on their wellness journey, help our programs continue to grow, and be a force for change in the communities we serve.”

Over the past four years, thousands of Walmart associates have transformed their lives by participating in the ZP Challenge, a series of 21-day programs that encourages and rewards associates and their families to improve their overall wellbeing by making better choices every day in the categories of fitness, family, food, and money. Building on the success of this initiative, Walmart will offer its associates using ZP with access to Sharecare, providing them with even more robust health and wellness resources to help them live their healthiest, happiest, most productive lives.

“Given the current state of health in the United States, large employers, in particular, must be willing to deliver their employees with relevant and personalized experiences, and when it comes to making good on that commitment, Walmart bears the gold standard,” said Jeff Arnold, co-founder, chairman and CEO of Sharecare. “We look forward to building on the foundation Walmart has laid for its associates by using Sharecare to amplify the improvements they are making in their lives each day and create a whole new value for the currency of good health.”

Walmart also will provide its associates and their families, alumni, and the community at large with full access to Sharecare to help each of them better understand, track, and improve their health, no matter where they are in their health journey. The Sharecare app will provide each person with timely and actionable steps to improve their health through innovative tools, health trackers and content, which will include news articles, tips, and programs inspired by and featuring Walmart associates who have positively impacted their lives with ZP. Additionally, later this year, Walmart will feature Sharecare in its Walmart Wellness Day quarterly in-store events, which offer a unique experience for busy families to learn how they can make positive changes in their health to save money and live better.

“As we have learned from our research through the Gallup-Sharecare Well-Being Index, a person’s holistic wellbeing is defined by five essential elements – purpose, social, financial, community, and physical – and when those elements are in alignment, individuals and places exhibit greater adaptability to change, resiliency, and productivity in the workplace, among other benefits,” said Dan Witters, research director for the Gallup-Sharecare Well-Being Index. “As the nation’s single largest employer with more than 1.5 million associates, Walmart and Sharecare have the potential to disrupt the status quo of workplace wellness and transform the health not only of the communities in which Walmart operates, but also, ultimately, our country.”

About Walmart

Walmart Inc. (NYSE: WMT) helps people around the world save money and live better – anytime and anywhere – in retail stores, online, and through their mobile devices. Each week, nearly 270 million customers and members visit our more than 11,700 stores under 59 banners in 28 countries and eCommerce websites. With fiscal year 2018 revenue of $500.3 billion, Walmart employs approximately 2.3 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity. Additional information about Walmart can be found by visiting http://corporate.walmart.com, on Facebook at http://facebook.com/walmart and on Twitter at http://twitter.com/walmart. 

About Sharecare

Sharecare is the digital health company that helps people manage all their health in one place. The Sharecare platform provides each person – no matter where they are in their health journey – with a comprehensive and personalized health profile where they can dynamically and easily connect to the information, evidence-based programs and health professionals they need to live their healthiest, happiest and most productive life. In addition to providing individual consumers with direct access to award-winning and innovative frictionless technologies, scientifically validated clinical protocols and best-in-class coaching tools, Sharecare also helps providers, employers and health plans effectively scale outcomes-based health and wellness solutions across their entire populations. To learn more, visit www.sharecare.com.

Highmark partners with Sharecare to provide personalized digital health solution to members

PITTSBURGH, Pa. (May 3, 2018) – Highmark Inc. has entered into a six-year partnership with Sharecare, the digital health company helping people manage all their health in one place, to exclusively offer innovative, personalized health and wellness solutions to its employer group customers in Pennsylvania, Delaware and West Virginia. Additionally, beginning January 1, 2019, Highmark members will have access to Sharecare’s personalized mobile and web-based platform that will help them better manage and understand their health, and provide timely and actionable steps to improve it, no matter where they are in their health journey.

“Consumers are more active in their own health care, but they are challenged with credible real-time information to help with health care decisions,” said Dr. Charles DeShazer, senior vice president and chief medical officer for Highmark. “Sharecare is laser focused to meet consumer expectations and ensure an exceptional member experience, and further sets its platform apart with personalized articles, videos and health content from trusted sources like the National Institutes of Health, American Heart Association and Centers for Disease Control – all through the smartphone and in the palm of your hand.”

Sharecare’s real-time data and personalized messages are also beneficial to employers, who are looking for ways to keep employees engaged, healthy and productive.

“We are excited to offer Sharecare to our customers with easy to implement wellness programs that produce meaningful outcomes,” said Matthew J. Rhenish, president, national and specialty markets, Highmark Inc. “Through a personalized, mobile experience, employers will be able to reach and engage their entire workforce, motivate employees to make positive health changes, and measure the results.”

Each member starts by taking Sharecare’s proprietary, scientifically-validated health risk assessment, RealAge, which calculates the actual age of their body versus their chronological age. Based on their RealAge results, the member receives personalized information, actionable plans and programs, and multimedia content from leading health experts and organizations to support them in their health journey. Utilizing technology already built into the smartphone, Sharecare helps the member track daily markers that have the biggest impact on their health, including sleep, stress and steps, as well as diet, blood pressure and medications.

Sharecare will be offered as the digital companion to Well360, Highmark’s comprehensive care management platform, which helps members close gaps in care, access appropriate care and decrease health risks. Whether used via mobile app or the web, Sharecare gathers – with the member’s permission – important information and dynamic data that improves Highmark’s ability to provide targeted care management solutions and efficiently coordinate care for members. Within Sharecare, members also can access their other health benefits provided by Highmark, making it more convenient than ever to engage in and manage their health.

“Highmark shares our vision to improve the health of diverse populations by engaging the member, and leveraging data-driven insights to provide people with real-time access to the tools and resources they need to best manage their health,” said Jeff Arnold, co-founder, chairman and CEO of Sharecare. “We are excited to partner with an organization as committed to its members as Highmark, and are eager to use our integrated platform to deliver Highmark customers and members with a comprehensive experience that ultimately will result in better outcomes and reduced costs.”

“Employers that offer Sharecare and Well360 will see healthier employees through more connected care, improved access to the right care and a personalized health care experience,” continued Dr. DeShazer. “Reward programs for achieving wellness goals, and employee challenges – such as a biggest loser contest – offered by Highmark can also help keep employees engaged in the program.”

“The goal is to transform the approach to health from episodic – I go to the doctor when I’m sick – to I understand my health, I’m managing my health and I’m taking action every day to improve my health,” he said. “We’re very fortunate to have found a perfect partner in Sharecare to help us do that.”

The Sharecare partnership is just the latest transformative effort by Highmark. The recently-launched Doctor Match, an innovative online tool to help consumers find the right doctor, is helping to make it easier for consumers to switch to a doctor that fits their needs and health care philosophy. Highmark is also seeing great success with its True Performance physician reimbursement program that is lowering costs and reducing ER visits and hospital stays.

About Highmark Inc.

Highmark Inc. and its health insurance subsidiaries and affiliates collectively are among the ten largest health insurers in the United States and comprise the fourth-largest Blue Cross and Blue Shield-affiliated organization. Highmark Inc. and affiliates operate health insurance plans in Pennsylvania, Delaware and West Virginia that serve 5 million members and hundreds of thousands of additional members through the BlueCard® program. Its diversified businesses serve group customer and individual needs across the United States through dental insurance, vision care and other related businesses. Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. For more information, visit www.highmark.com.

About Sharecare

Sharecare is the digital health company that helps people manage all their health in one place. The Sharecare platform provides each person – no matter where they are in their health journey – with a comprehensive and personalized health profile where they can dynamically and easily connect to the information, evidence-based programs and health professionals they need to live their healthiest, happiest and most productive life. In addition to providing individual consumers with direct access to award-winning and innovative frictionless technologies, scientifically validated clinical protocols and best-in-class coaching tools, Sharecare also helps providers, employers and health plans effectively scale outcomes-based health and wellness solutions across their entire populations. To learn more, visit www.sharecare.com.

Mercy Health Expands Partnership with InTouch Health to Offer Behavioral Health Virtual Care Services

Partnership enables streamlined telehealth at eight locations within Mercy Health's care network

SANTA BARBARA, Calif., April 24, 2018 /PRNewswire/ -- InTouch Health, the leading enterprise virtual care platform, today announces its expanded partnership with Mercy Health to deliver inpatient behavioral health virtual care services to Mercy Hospitals across the Northwest Ohio region.

"Mercy Health is committed to serving the whole patient – mind, body, and spirit," said Bob Baxter, President and CEO of Mercy Health – Toledo. "We look forward to utilizing InTouch Health to offer telepsychiatry services to our patients who will now have improved mental health care access when they need it.  This innovative technology-based telehealth model will continue to allow effective and timely care for our patients as they seek help for themselves or a loved one."

Utilizing the InTouch Virtual Care Platform, Lighthouse Telehealth (a subsidiary of Harbor) Physicians and Advanced Practitioners will provide psychiatric consultative services within the emergency departments and inpatient units at Mercy Health's three metro Toledo hospitals: Mercy Health – St. Vincent Medical Center, Mercy Health – St. Charles Hospital and Mercy Health – St. Anne Hospital, as well as Mercy Health hospitals in Defiance, Tiffin, and Willard, Ohio.

"We have worked with InTouch Health over the past few years to enable telestroke services, and we look forward to expanding our work to deliver inpatient psychiatric telehealth on a secure and reliable platform," said Ateeq Haseeb, MD, MBA CPE, Chief Medical Informatics Officer at Mercy Health – Toledo. "Our experience with InTouch Health has been exceptional. InTouch Health's easy to use technology allows our clinicians to focus on delivering the best care to our patients, which is what we at Mercy Health strive to do every day."

"We look forward to our expanded relationship with Mercy Health, a leading care provider, to enable broader virtual care services on a single platform," said Joseph M. DeVivo, CEO at InTouch Health. "We know that there is a mental health crisis in the United States, and we believe virtual care can help relieve many of the access barriers patients face. We applaud Mercy Health for taking the steps to expand their behavioral health services to increase access and improve patient care, all while allowing patients to remain in their local communities."

Mental illness is one of the leading causes of disability in the U.S. with nearly one in five Americans having a mental health condition and less than half actually receiving appropriate treatment. Lack of behavioral health providers is cited as a common barrier to receiving care. Leveraging telehealth can help alleviate that barrier because it brings behavioral health specialists to more locations so they can meet patients in any location at any time.

InTouch Health will be launching a new Behavioral Health Solution at the American Telemedicine Association Annual Conference in Chicago. The InTouch Behavioral Health Solution addresses the demand for qualified mental health providers at every level of the care continuum, from outpatient and home, to emergency departments and inpatient care, the latter of which Mercy Health – Toledo is implementing. InTouch Health will also be showcasing the configurable InTouch Operating System and turnkey virtual care solutions for stroke, specialist follow-up, cardiology, ICU/critical care, direct-to-patient, employer clinic, and direct-to-consumer. Visit booth #2002 at ATA18 for demos of these latest solutions.

About InTouch Health
InTouch Health, the 2018 KLAS Category Leader for Virtual Care Platforms, delivers its HITRUST CSF Certified telehealth services to health systems with a full range of solutions to efficiently deliver Consumer, Specialty, and Emergent virtual care in any care environment. InTouch Health provides the most reliable, dedicated cloud-based network and virtual care solutions that ensure connectivity for health systems, providers, and patients at all times. Today, InTouch Health supports more than 1,950 care locations around the world – including many of the top 20 health systems – as they deploy telehealth programs across their enterprises. InTouch Health has surpassed 1.84 million network sessions, which includes 940,000 telehealth virtual care sessions over the InTouch Telehealth Network. To learn more, please visit: www.intouchhealth.com.

About Mercy Health – Toledo
Mercy Health – Toledo is a member of Mercy Health, the largest health system in Ohio and the fourth largest employer in the state. Locally, Mercy Health is based in Toledo, Ohio and serves 20 counties in Northwest Ohio and Southeast Michigan. Mercy Health – Toledo provides comprehensive primary and critical care services to residents as well as a robust physician group, Mercy Health Physicians, Life Flight critical air transport services and Mercy Collegeof Ohio. Mercy Health – Toledo is proud to have provided nearly $110 million in community benefit in 2016 which includes charity care and community health services. With approximately 8,800 employees; 300 employed physicians; and 2,200 medical staff members, Mercy Health has been part of the Northwest Ohio community it serves for more than 162 years. Please visit mercy.com for additional information and connect with Mercy Health – Toledo on Facebook, Twitter @mercynwohio and Instagram.

SOURCE InTouch Health

McLaren Health Care Selects InTouch Health for Consumer Virtual Care Services

SANTA BARBARA, Calif., April 26, 2018 /PRNewswire/ -- InTouch Health, the leading enterprise virtual care platform, today announces McLaren Health Care, a Michigan-based integrated health network, has expanded its telehealth offerings to implement InTouch Health's new Consumer solutions.

McLaren Health Care's virtual care expansion also coincides with the health system's three-year anniversary of its work with InTouch Health to deliver acute telehealth services for stroke, neurointensive care, ICU, pulmonary, and cardiology specialist consults.

"InTouch Health has demonstrated their virtual care expertise through our work together these past three years, and with their new Consumer solutions, we will be able to leverage our telehealth infrastructure investment to streamline our services on a single platform," said Cheryl Ellegood, VP Corporate Service Lines at McLaren Health Care. "We selected InTouch Health to expand our telehealth services to low-acuity care to create a seamless experience for nearly any patient care solution via the web using mobile devices or a desktop. We are excited to offer our patients an on-demand virtual care option to make it easier for them to seek care, wherever they may be."

"We are honored McLaren Health Care, a leading healthcare provider, continues to put their trust in InTouch Health to manage their multi-specialty enterprise telehealth programs," said Joseph M. DeVivo, CEO at InTouch Health. "We know health systems want a single, enterprise-wide virtual care solution for a multitude of reasons – from streamlining the clinician and patient user experience, to managing a single partner rather than several, and to build upon one telehealth infrastructure. We're pleased to continue our work together to advance our shared vision for virtualizing care."

McLaren Health Care will use the InTouch Direct-to-Patient Solution for scheduled follow-up visits with primary care physicians and specialists, and for scheduled consults with specialists. This will allow rural satellite clinics within the McLaren Health Care network to provide better and more timely access for patients who need specialist consults with the added convenience of remaining in their communities.

McLaren's use of the InTouch Direct-to-Consumer Solution will enable patients throughout the state of Michigan to initiate on-demand virtual care anytime, anywhere.

"As patients increasingly expect access to telehealth services, we are expanding our work with InTouch Health to provide our patients with more convenient ways to access care, and to give our clinicians a secure and reliable tool to reach patients anywhere," said Mark S. O'Halla, Executive Vice President and COO at McLaren Health Care. "Our relationship with InTouch Health truly has been a partnership, and we look forward to continuing our work together to provide patients with the best telehealth experience possible."

"We're thrilled McLaren Health Care has expanded their partnership to leverage the InTouch Virtual Care Platform to drive consumer engagement throughout Michigan," said Steve Cashman, EVP Marketing and Consumer Solutions at InTouch Health. "InTouch Health tackled the toughest challenge first by pioneering acute care telemedicine. Having McLaren align with our single platform philosophy to displace other telehealth companies who started in low acuity is powerful validation."

InTouch Health will be providing demos of its Consumer solutions at the American Telemedicine Association Annual Conference in Chicago. InTouch Health will also be showcasing the configurable InTouch Operating System and turnkey virtual care solutions for stroke, specialist follow-up, cardiology, behavioral health, and employer clinic. Visit booth #2002 at ATA18 for demos of these latest solutions.

About InTouch Health
InTouch Health, the 2018 KLAS Category Leader for Virtual Care Platforms, delivers its HITRUST CSF Certified telehealth services to health systems with a full range of solutions to efficiently deliver Consumer, Specialty, and Emergent virtual care in any care environment. InTouch Health provides the most reliable, dedicated cloud-based network and virtual care solutions that ensure connectivity for health systems, providers, and patients at all times. Today, InTouch Health supports more than 1,950 care locations around the world – including many of the top 20 health systems – as they deploy telehealth programs across their enterprises. InTouch Health has surpassed 1.84 million network sessions, which includes 940,000 telehealth virtual care sessions over the InTouch Telehealth Network. To learn more, please visit: www.intouchhealth.com.

About McLaren Health Care
McLaren Health Care, headquartered in Grand Blanc, Michigan, is a fully integrated health network committed to quality, evidence-based patient care and cost efficiency. The McLaren system includes 14 hospitals, ambulatory surgery centers, imaging centers, a 490-member employed primary and specialty care physician network, commercial and Medicaid HMOs covering more than 620,000 lives in Michigan and Indiana, home health and hospice providers, retail medical equipment showrooms, pharmacy services, and a wholly owned medical malpractice insurance company. McLaren operates Michigan's largest network of cancer centers and providers, anchored by the Barbara Ann Karmanos Cancer Institute, one of only 49 NCI-designated comprehensive centers in the U.S. McLaren has 26,000 employees and more than 52,500 network providers. Its operations are housed in more than 350 facilities serving the entire Lower Peninsula along with a portion of the Upper Peninsula. Learn more at www.mclaren.org.

View original content with multimedia:http://www.prnewswire.com/news-releases/mclaren-health-care-selects-intouch-health-for-consumer-virtual-care-services-300637191.html

SOURCE InTouch Health

INTOUCH HEALTH “HIGHEST-PERFORMING VENDOR”(1) IN KLAS® TELEHEALTH VIRTUAL CARE PLATFORMS 2017 REPORT

KLAS performance report rates telehealth providers’ ability to expand virtual care

SANTA BARBARA, Calif., October 17, 2017 – InTouch Health, the leading enterprise telehealth platform, announced today the company is profiled as the highest rated vendor included in “Telehealth Virtual Care Platforms 2017,” a performance report published by KLAS. KLAS interviewed 108 unique healthcare organizations in the study of nine leading telehealth vendors providing services in virtual clinics, urgent care and telespecialty consultations.

“Our success as the highest rated telehealth vendor is attributable to over a decade of hard work from the dedicated employees at InTouch Health who keep the patients and physicians first in everything that we do. We are honored to hear that 100% of our clients surveyed said that we keep our promises. That is rarely seen in KLAS research,” (2 & 11) said Joseph M. DeVivo, InTouch Health CEO.  “Every provider who puts their trust in our solutions, our people, and our integrity knows that we are laser focused on delivering the world’s most secure, reliable and scalable telehealth solution. It’s an exciting time as we release new products to expand both the breadth and depth of our offering. We envision a telehealth offering that allows hospitals to deliver low and high acuity care from home to hospital and back home again.”

With an overall score of 89.8, InTouch came in ahead of competitors because of the adaptability of the InTouch Telehealth Network and strong customer support for clients through every phase of implementation (2 & 3). InTouch Health’s network enables clinicians to deliver high quality care in high and low acuity settings across service lines, such as behavioral health, cardiology, neurology (telestroke), infectious disease, endocrinology, wound care, and rheumatology.

The report notes that, for healthcare organizations, telehealth reduces delivery costs, increases access to new patients, and allows organizations to deliver better quality care.

Highlights from the report data include:

  • 100% of clients report they would purchase again from InTouch Health (4)
  • Top performer in acute care telespecialty consultations (5)
  • Highest rated vendor for service and support (6)
  • Highest rated vendor for ease of use (7)
  • Highest rated vendor for overall product quality (8)
  • Highest rated vendor for functionality and upgrades (9)
     

Ease of IT integration

Several customers found that the solutions InTouch provided made it easier for the internal IT teams to adapt to telehealth, a typical problem between healthcare systems and telehealth providers.

“With the total solution that InTouch Health offers, our internal IT team essentially does not have to touch the product, and this is very appealing to our IT staff. The InTouch Health team provides all of the ongoing maintenance and support for the system.” (10)

Network reliability

Other report interviewees commended the company for the reliability and consistency of the InTouch Telehealth Network. After previous issues with other vendors, they chose InTouch in order to make patient care more efficient and streamlined.

“The biggest benefit of having InTouch Telehealth network is that it works consistently… Every time we connect to a cart, it works. That is a big benefit for us compared to what we were used to with our previous telehealth system.” (11)

Turning telehealth from cost center into profit center

Additional findings from the report included many different benefits from using InTouch Health. Clients are seeing improved patient outcomes, improved access to care, and improved patient satisfaction. With shorter wait times required for patients to see their providers, InTouch Telehealth Network speeds up the delivery of care, and some users saw increased revenue for certain services at the hospital level (12).

 To learn more or access the full KLAS report, please visit:  

https://klasresearch.com/report/telehealth-virtual-care-platforms-2017/1161

About InTouch Health

InTouch Health provides its world class 24/7 monitored InTouch Telehealth Network, comprised of regulated telehealth systems, clinical workflow solutions and software, and managed services to hospitals and health care systems for the delivery of clinical care, anytime, anywhere. Today, InTouch Health supports more than 130 health care systems, 5,800 network users and 1,600 care locations around the world as they deploy telehealth programs across their enterprises. InTouch Health has surpassed 850,000 network sessions, and 760,000 potentially life-saving telehealth sessions over the InTouch Telehealth Network, and is forecasted to manage more than 270,000 clinical sessions in 2017.  To learn more, please visit: www.intouchhealth.com

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider's voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. Follow KLAS on Twitter or visit www.klasresearch.com for report details.

__

(1)   P. 19: “…(the highest fully rated product in this report)
(2)   P. 37
(3)   P. 4
(4)   Figure 23
(5)   P.19
(6)   Figure 66
(7)   Figure 66
(8)   Figure 66
(9)   Executive summary – item #2
(10)P. 130
(11) P. 131
(12)P. 130

lifeIMAGE Becomes New Technology Partner with Google Cloud

November 1, 2017

The new partnership provides an opportunity to explore ways to improve patient outcomes and population health.

NEWTON, MA. – November 1, 2017 – lifeIMAGE, one of the largest medical information networks for images and clinical evidence, announced a new collaboration today with Google Cloud. lifeIMAGE is working with Google Cloud Platform (GCP) to help mature global precision medicine initiatives by exploring point of care capabilities for physicians, and to aid researchers in the effort to identify, share and improve their understanding of population health.

By joining as a Google Cloud Technology Partner, lifeIMAGE has the opportunity to leverage GCP across our various solutions such as Mammosphere, a patient engagement tool that supports women’s health in mammography. In addition, lifeIMAGE now has the capability to use GCP as an extension of our hybrid network hosting strategy for our customer base.

“Ultimately, what this collaboration aims to achieve is to help clinicians take better care of patients,” said Matthew Michela, President and Chief Executive Officer of lifeIMAGE. “For example, our relationship with Google Cloud will enable us to more easily identify patterns of interest across billions of images to help clinicians make better treatment decisions in real time.”

lifeIMAGE is one of the largest medical information exchange networks that enables access to images and clinical information to more than 150,000 providers at 1,400 facilities across clinical specialties and across institutions globally. By processing billions of images and managing millions of clinical encounters across institutional boundaries, lifeIMAGE enables clinicians, patients and data scientists to make more informed decisions.

With its large digital ecosystem, lifeIMAGE supports the health care innovation lifecycle through our ability to gain novel insights from the data passing through our network. This new relationship with Google Cloud also strengthens the regulatory, compliance, and data management collaborations with our global customers, particularly in life sciences.

“The collaboration with the Google Cloud Platform framework will focus on strategic opportunities to reduce the healthcare cost burden, to manage partner integrations in the digital ecosystem, and to improve the quality of our insights from genomic, radiomic and clinical data sets,” said Janak Joshi, Chief Technology Officer for lifeIMAGE. “We enable machine learning by providing access, scale and speed that are available 24 hours a day, every day.”

For more information about the new collaboration come visit us at the lifeIMAGE or Google Cloud booth at the Radiological Society of North America (RSNA) annual meeting in Chicago from November 26 to December 1.

About lifeIMAGE

lifeIMAGE is a leading medical image exchange solution connecting health care networks, providers and patients to imaging records, regardless of where exams are performed or stored. We enable access to images and clinical information to more than 150,000 providers at 1,400 facilities across clinical specialties and across institutions globally. Providers use lifeIMAGE to improve the quality and timeliness of care, expand referral business, and eliminate wasteful spending. For more information about lifeIMAGE, please visit: www.lifeimage.com, check out our blog or follow us on TwitterFacebook, or LinkedIn.

Contact:

Judy Chong
VP, Marketing for lifeIMAGE
617-244-8411 x218
media@lifeimage.com

WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma

New results published in Gastrointestinal Endoscopy

SOURCE: CDx Diagnostics

SUFFERN, NY — (Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of Barrett's esophagus today announced the publication of new, pivotal, multicenter, crossover data in the latest issue of Gastrointestinal Endoscopy. The study found that WATS3D increased the detection of High-Grade Dysplasia and Esophageal Adenocarcinoma (HGD/EAC) by more than 400% compared to the standard Seattle protocol random forceps biopsy, even when those random biopsies are carefully performed in academic centers by some of the world's most experienced endoscopists.

"At the current time, endoscopists rely solely on taking small random forceps biopsies at 1-2 cm intervals, leaving more than 96% of the endoscopically suspect area completely untested. The publication of this study underscores the severe limitations of our current random biopsy protocol as well as the value of taking a few extra minutes to add the WATS3Dprocedure as a standard of care," said lead author Prashanth R. Vennalaganti, MD, of Kansas City VA Medical Center and University of Kansas School of Medicine, Kansas City, Missouri.

The multi-center, prospective, randomized, tandem study was conducted in 16 major academic US GI centers. In the study, WATS3D detected 29 cases of HGD/EAC while the Seattle random forceps biopsy detected only seven such cases among 160 high-risk patients undergoing Barrett's esophagus surveillance.

"These results are quite compelling," said Robert D. Odze, MD, Director of the GI Pathology Division at the Brigham and Women's Hospital and Professor of Pathology at the Harvard Medical School who was not a participant in the study. He continued, "WATS not only addresses the sampling error inherent in relying on random forceps biopsies, its three-dimensional computer assisted analysis of the tissue sample provides the GI pathologist with diagnostic information that is not typically available using standard tissue based histopathology. We look forward to implementing this advance in gastroenterology and GI pathology to enhance routine care for our own practitioners."

"I can think of very few high impact studies in the field of Barrett's esophagus that should change how gastroenterologists, both community-based and academic, care for their patients, and this study is one of them," said Michael S. Smith, MD, MBA, incoming Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai St. Luke's Hospitals in New York, who participated in the study. "These robust data demonstrate we have a tool that markedly improves our ability to detect dysplasia and cancer within Barrett's well beyond the error-prone Seattle protocol."

"Participation in this multicenter study, and further experience using WATS3D in my large Barrett's practice, has resulted in its incorporation into my routine clinical care," said Dr. Charles Lightdale, MD of the Columbia University Medical Center, New York. He continued, "Routine clinical use of WATS3D continues to demonstrate increased diagnostic yield in my patients, including in post-ablation surveillance. I see no reason why every academic and community gastroenterologist should not be using this rapidly performed, easily implemented procedure today to improve the diagnosis of Barrett's esophagus and dysplasia, so patients can be directed to appropriate endoscopic surveillance or therapy to prevent esophageal cancer."

"The current standard of care forces gastroenterologists to rely on chance, hoping that one of their small random forceps biopsies will happen to land on a highly focal area of precancer that may exist in their patient's esophagus," said Mark Rutenberg, Founder and CEO of CDx Diagnostics, the developer of the WATS3D diagnostic system. "Now that we can more easily treat esophageal precancer though endoscopic ablation, the remaining obstacle to preventing the most rapidly growing cancer in the US is to more reliably identify those GERD and Barrett's patients with these still harmless but precancerous changes so that we can treat them in time to prevent their progression to adenocarcinoma. These results clearly demonstrate that WATS3D can very effectively help to fill that critical gap in current routine GI care."

Dr. Charles Lightdale, MD, Columbia University Medical Center, summarizes newly published data from a pivotal multicenter, prospective randomized crossover study that demonstrates the effectiveness of WATS3D vs. the Seattle random biopsy protocol.

 

About CDx Diagnostics

 CDx Diagnostics' mission is to provide clinicians with easily implemented, cost effective, tools to preempt cancer through enhanced detection precancerous change. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. CDx tests for precancerous change require only a few minutes of practice time, are highly cost effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Routine clinical use of CDx testing in the oral cavity and esophagus has prevented thousands of cancers, and application of the CDx diagnostic platform to prevent cancers of the throat, bile duct, liver, pancreas, and stomach, is currently in progress.

About WATS3D

CDx Diagnostics' WATS3D biopsy addresses the major sampling error inherent in current random forceps biopsy testing of the esophagus. In just a few minutes, endoscopists can easily obtain a wide area, full-thickness transepithelial tissue sample for computer-assisted 3D laboratory analysis. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both Barrett's esophagus and esophageal dysplasia. The high sensitivity and interobserver agreement of WATS3D is due to the larger tissue area sampled, and the proprietary 3-Dimensionial computer imaging system that is based on an algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.wats3d.com.

 

CONTACT INFORMATION

Contact:
Chantal Beaudry or Amy Feldman for CDx Diagnostics
cbeaudry@lazarpartners.com
afeldman@lazarpartners.com
212-867-1762